Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.
Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.
复制标题
DOI：
10.1159/000450974
复制
发表时间：
2016-09
影响因子：
0.8
通讯作者：
Aiba S
中科院分区：
文献类型：
--
作者：
Furudate S;Fujimura T;Kambayashi Y;Hidaka T;Hashimoto A;Aiba S
由于nivolumab显著延长了转移性黑色素瘤患者的生存期，因此给予nivolumab的患者数量正在增加，但接受nivolumab单药治疗的患者中只有30-40%经历了客观的肿瘤消退。因此，增强其抗肿瘤免疫应答是皮肤肿瘤学家的极大兴趣。在这份报告中，我们介绍了一例肺多发性转移性黑色素瘤的病例，该病例成功地用纳武单抗（2 mg/kg，每3周一次，持续12周）治疗，随后用伊匹单抗（3 mg/kg，每3周一次，持续9周）治疗，但伴有严重的肝功能障碍。
Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30–40% of patients who received nivolumab monotherapy experienced objective tumor regression. Therefore, enhancing its anti-tumor immune response is of great interest to dermato-oncologists. In this report, we present a case of multiple metastatic melanomas in the lung successfully treated with nivolumab (2 mg/kg every 3 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 9 weeks), but with severe liver dysfunction.